Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs.

Kolosenko I, Fryknäs M, Forsberg S, Johnsson P, Cheon H, Holvey-Bates EG, Edsbäcker E, Pellegrini P, Rassoolzadeh H, Brnjic S, Larsson R, Stark GR, Grandér D, Linder S, Tamm KP, De Milito A.

Int J Cancer. 2015 Feb 15;136(4):E51-61. doi: 10.1002/ijc.29161. Epub 2014 Sep 4.


Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.

Brnjic S, Mazurkiewicz M, Fryknäs M, Sun C, Zhang X, Larsson R, D'Arcy P, Linder S.

Antioxid Redox Signal. 2014 Dec 10;21(17):2271-85. doi: 10.1089/ars.2013.5322. Epub 2013 Oct 17.


Autophagy is a protective mechanism for human melanoma cells under acidic stress.

Marino ML, Pellegrini P, Di Lernia G, Djavaheri-Mergny M, Brnjic S, Zhang X, Hägg M, Linder S, Fais S, Codogno P, De Milito A.

J Biol Chem. 2012 Aug 31;287(36):30664-76. doi: 10.1074/jbc.M112.339127. Epub 2012 Jul 3.


The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.

Hernlund E, Olofsson MH, Fayad W, Fryknäs M, Lesiak-Mieczkowska K, Zhang X, Brnjic S, Schmidt V, D'Arcy P, Sjöblom T, De Milito A, Larsson R, Linder S.

Eur J Cancer. 2012 Feb;48(3):396-406. doi: 10.1016/j.ejca.2011.11.013. Epub 2011 Dec 7.


Inhibition of proteasome deubiquitinating activity as a new cancer therapy.

D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S.

Nat Med. 2011 Nov 6;17(12):1636-40. doi: 10.1038/nm.2536.


Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment.

Gullbo J, Fryknäs M, Rickardson L, Darcy P, Hägg M, Wickström M, Hassan S, Westman G, Brnjic S, Nygren P, Linder S, Larsson R.

Biochem Pharmacol. 2011 Jul 15;82(2):139-47. doi: 10.1016/j.bcp.2011.04.003. Epub 2011 Apr 22.


Chemical biology suggests a role for calcium signaling in mediating sustained JNK activation during apoptosis.

Brnjic S, Olofsson MH, Havelka AM, Linder S.

Mol Biosyst. 2010 May;6(5):767-74. doi: 10.1039/b920805d. Epub 2010 Feb 9. Review.


Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.

Fayad W, Fryknäs M, Brnjic S, Olofsson MH, Larsson R, Linder S.

PLoS One. 2009 Oct 2;4(10):e7238. doi: 10.1371/journal.pone.0007238.


Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model.

Fayad W, Brnjic S, Berglind D, Blixt S, Shoshan MC, Berndtsson M, Olofsson MH, Linder S.

Int J Cancer. 2009 Nov 15;125(10):2450-5. doi: 10.1002/ijc.24627.


Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.

Olofsson MH, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedra R, Wilkinson RW, Mundt KE, Busk M, Dive C, Linder S.

Cancer Biomark. 2009;5(3):117-25. doi: 10.3233/CBM-2009-0597.


Charting calcium-regulated apoptosis pathways using chemical biology: role of calmodulin kinase II.

Olofsson MH, Havelka AM, Brnjic S, Shoshan MC, Linder S.

BMC Chem Biol. 2008 Aug 1;8:2. doi: 10.1186/1472-6769-8-2.


Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.

Maruwge W, D'Arcy P, Folin A, Brnjic S, Wejde J, Davis A, Erlandsson F, Bergh J, Brodin B.

Onco Targets Ther. 2008 Nov 1;1:67-78.

Supplemental Content

Loading ...
Support Center